Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
Ovarian cancer is a common cancer for females, and the incidence and mortality rates are on the rise. Many treatment strategies have been developed for ovarian cancer, including chemotherapy and immunotherapy, but they are often ineffective and prone to drug resistance. Protein ubiquitination is an important class of post-translation modifications that have been found to be associated with various human diseases and cancer development. Recent studies have revealed that protein ubiquitination is involved in the progression of ovarian cancer and plays an important role in the tumor immune process. Moreover, the combination of ubiquitinase/deubiquitinase inhibitors and cancer immunotherapy approaches can effectively reduce treatment resistance and improve treatment efficacy, which provides new ideas for cancer treatment. Herein, we review the role of protein ubiquitination in relation to ovarian cancer immunotherapy and recent advances in the use of ubiquitinase/deubiquitinase inhibitors in combination with cancer immunotherapy.
Wang Z, Guo E, Yang B, et al. Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: cervical, ovarian and uterine cancer. Gynecol Oncol. 2021;163(2):358–363.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–249.
Green DS, Ning F, Duemler A, et al. Intraperitoneal monocytes plus IFNs as a novel cellular immunotherapy for ovarian cancer: mechanistic characterization and results from a phase Ⅰ clinical trial [published correction appears in Clin Cancer Res. 2023 Jan 17;29(2):501]. Clin Cancer Res. 2023;29(2):349–363.
Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Front Immunol. 2020;11:577869.
Lee SM, Lee S, Cho HW, et al. Application of immune checkpoint inhibitors in gynecological cancers: what do gynecologists need to know before using immune checkpoint inhibitors? Int J Mol Sci. 2023;24(2):974.
Schossig P, Coskun E, Arsenic R, et al. Target selection for T-cell therapy in epithelial ovarian cancer: systematic prioritization of self-antigens. Int J Mol Sci. 2023;24(3):2292.
Shen Y, Liu G, Zhang Q, Tian X, Ouyang L, Zhang L. Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer. Immunol Lett. 2023;255:1–9.
Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian cancer immunotherapy and personalized medicine. Int J Mol Sci. 2021;22(12):6532.
Rajtak A, Ostrowska-Leśko M, Żak K, Tarkowski R, Kotarski J, Okła K. Integration of local and systemic immunity in ovarian cancer: implications for immunotherapy. Front Immunol. 2022;13:1018256.
Liu YC. Ubiquitin ligases and the immune response. Annu Rev Immunol. 2004;22:81–127.
Han S, Wang R, Zhang Y, et al. The role of ubiquitination and deubiquitination in tumor invasion and metastasis. Int J Biol Sci. 2022;18(6):2292–2303.
Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425–479.
Wang Z, Liu P, Inuzuka H, Wei W. Roles of F-box proteins in cancer. Nat Rev Cancer. 2014;14(4):233–247.
Ji M, Zhao Z, Li Y, et al. FBXO6-mediated RNASET2 ubiquitination and degradation governs the development of ovarian cancer. Cell Death Dis. 2021;12(4):317.
Ji J, Shen J, Xu Y, et al. FBXO2 targets glycosylated SUN2 for ubiquitination and degradation to promote ovarian cancer development. Cell Death Dis. 2022;13(5):442.
Li X, Yang KB, Chen W, et al. CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression. Autophagy. 2021;17(12):4323–4340.
Ji M, Zhao Z, Li Y, et al. FBXO16-mediated hnRNPL ubiquitination and degradation plays a tumor suppressor role in ovarian cancer. Cell Death Dis. 2021;12(8):758.
Sun T, Liu Z, Bi F, Yang Q. Deubiquitinase PSMD14 promotes ovarian cancer progression by decreasing enzymatic activity of PKM2. Mol Oncol. 2021;15(12):3639–3658.
Wang X, Tokheim C, Gu SS, et al. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell. 2021;184(21):5357–5374.e22.
Hu X, Wang J, Chu M, Liu Y, Wang ZW, Zhu X. Emerging role of ubiquitination in the regulation of PD-1/PD-L1 in cancer immunotherapy. Mol Ther. 2021;29(3):908–919.
Song M, Yeku OO, Rafiq S, et al. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nat Commun. 2020;11(1):6298.
Matsuura K, Huang NJ, Cocce K, Zhang L, Kornbluth S. Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin. Oncogene. 2017;36(12):1698–1706.
Zhang Q, Wang W, Gao Q. β-TRCP-mediated AEBP2 ubiquitination and destruction controls cisplatin resistance in ovarian cancer. Biochem Biophys Res Commun. 2020;523(1):274–279.
Wu AY, Gu LY, Cang W, et al. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation. J Exp Clin Cancer Res. 2019;38(1):176.
Chen L, Gao W, Sha C, et al. SIAH1-mediated RPS3 ubiquitination contributes to chemosensitivity in epithelial ovarian cancer. Aging (Albany NY). 2022;14(15):6202–6226.
Swatek KN, Komander D. Ubiquitin modifications. Cell Res. 2016;26(4):399–422.
Chau V, Tobias JW, Bachmair A, et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science. 1989;243(4898):1576–1583.
Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 1994;79(1):13–21.
Kirisako T, Kamei K, Murata S, et al. A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J. 2006;25(20):4877–4887.
Buneeva O, Medvedev A. Atypical ubiquitination and Parkinson's disease. Int J Mol Sci. 2022;23(7):3705.
Park J, Cho J, Song EJ. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res (Seoul). 2020;43(11):1144–1161.
Clague MJ, Barsukov I, Coulson JM, Liu H, Rigden DJ, Urbé S. Deubiquitylases from genes to organism. Physiol Rev. 2013;93(3):1289–1315.
Yuan T, Yan F, Ying M, et al. Inhibition of ubiquitin-specific proteases as a novel anticancer therapeutic strategy. Front Pharmacol. 2018;9:1080.
Mevissen TET, Komander D. Mechanisms of deubiquitinase specificity and regulation. Annu Rev Biochem. 2017;86:159–192.
Du J, Fu L, Sui Y, Zhang L. The function and regulation of OTU deubiquitinases. Front Med. 2020;14(5):542–563.
Jiang Y, Wang C, Zhou S. Targeting tumor microenvironment in ovarian cancer: premise and promise. Biochim Biophys Acta Rev Cancer. 2020;1873(2):188361.
Yu T, Gan S, Zhu Q, et al. Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24. Nat Commun. 2019;10(1):4353.
Pan Z, Zhao R, Li B, et al. EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3. Mol Cancer. 2022;21(1):16.
Li B, Zhu L, Lu C, et al. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nat Commun. 2021;12(1):295.
Zhang P, Su T, Zhang S. Comprehensive analysis of prognostic value of MEX3A and its relationship with immune infiltrates in ovarian cancer. J Immunol Res. 2021;2021:5574176.
Li B, Qi ZP, He DL, et al. NLRP7 deubiquitination by USP10 promotes tumor progression and tumor-associated macrophage polarization in colorectal cancer. J Exp Clin Cancer Res. 2021;40(1):126.
Cortez JT, Montauti E, Shifrut E, et al. CRISPR screen in regulatory T cells reveals modulators of Foxp3. Nature. 2020;582(7812):416–420.
Montauti E, Weinberg SE, Chu P, et al. A deubiquitination module essential for Treg fitness in the tumor microenvironment. Sci Adv. 2022;8(47):eabo4116.
Chen B, Sang Y, Song X, et al. Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28. Theranostics. 2021;11(8):3932–3947.
Bai J, Liu T, Tu B, et al. Autophagy loss impedes cancer-associated fibroblast activation via downregulating proline biosynthesis. Autophagy. 2023;19(2):632–643.
Zhang H, Deng T, Liu R, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020;19(1):43.
Chen B, Zhu HY, Yang B, Cao J. The dichotomous role of immunoproteasome in cancer: friend or foe? Acta Pharm Sin B. 2022;13:1976–1989.
Dong J, Miao J, Miao Y, et al. Small molecule degraders of protein tyrosine phosphatase 1B and T-cell protein tyrosine phosphatase for cancer immunotherapy. Angew Chem Int Ed Engl. 2023;62(22):e202303818.
Kasuga Y, Ouda R, Watanabe M, et al. FBXO11 constitutes a major negative regulator of MHC class Ⅱ through ubiquitin-dependent proteasomal degradation of CIITA. Proc Natl Acad Sci U S A. 2023;120(24):e2218955120.
Mamrosh JL, Sherman DJ, Cohen JR, et al. Quantitative measurement of the requirement of diverse protein degradation pathways in MHC class Ⅰ peptide presentation. Sci Adv. 2023;9(25):eade7890.
Chen X, Lu Q, Zhou H, et al. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell. 2023;186(18):3903–3920.e21.
Wilson KR, Jenika D, Blum AB, et al. MHC class Ⅱ ubiquitination regulates dendritic cell function and immunity. J Immunol. 2021;207(9):2255–2264.
Wilson KR, Liu H, Healey G, et al. MARCH1-mediated ubiquitination of MHC Ⅱ impacts the MHC I antigen presentation pathway. PLoS One. 2018;13(7):e0200540.
Takahashi M, Lio CWJ, Campeau A, et al. The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING-IFN-β pathway. Nat Immunol. 2021;22(4):485–496.
Li JY, Zhao Y, Gong S, et al. TRIM21 inhibits irradiation-induced mitochondrial DNA release and impairs antitumour immunity in nasopharyngeal carcinoma tumour models. Nat Commun. 2023;14:865.
Ghosh M, Saha S, Li J, Montrose DC, Martinez LA. p53 engages the cGAS/STING cytosolic DNA sensing pathway for tumor suppression. Mol Cell. 2023;83(2):266–280.e6.
Apriamashvili G, Vredevoogd DW, Krijgsman O, et al. Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling. Nat Commun. 2022;13(1):1923.
Cassidy KB, Bang S, Kurokawa M, Gerber SA. Direct regulation of Chk1 protein stability by E3 ubiquitin ligase HUWE1. FEBS J. 2020;287(10):1985–1999.
Shearer RF, Typas D, Coscia F, et al. K27-linked ubiquitylation promotes p97 substrate processing and is essential for cell proliferation. EMBO J. 2022;41(9):e110145.
Chen S, Liu Y, Zhou H. Advances in the development ubiquitin-specific peptidase (USP) inhibitors. Int J Mol Sci. 2021;22(9):4546.
Ye Z, Chen J, Huang P, Xuan Z, Zheng S. Ubiquitin-specific peptidase 10, a deubiquitinating enzyme: assessing its role in tumor prognosis and immune response. Front Oncol. 2022;12:990195.
Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367(6477):eaax0182.
Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol. 2020;25(5):818–830.
Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol. 2019;16(5):430–441.
Gato-Cañas M, Zuazo M, Arasanz H, et al. PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell Rep. 2017;20(8):1818–1829.
Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465.
Huang LJ, Deng XF, Chang F, Wu XL, Wu Y, Diao QZ. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: a systematic review and meta-analysis. Medicine (Baltim). 2018;97(43):e12858.
Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022;22(3):174–189.
Sahin I, Zhang S, Navaraj A, et al. Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. Cell Death Dis. 2020;6:71.
Wang Z, Kang W, Li O, et al. Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. Acta Pharm Sin B. 2021;11(3):694–707.
De S, Holvey-Bates EG, Mahen K, Willard B, Stark GR. The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage. Proc Natl Acad Sci U S A. 2021;118(47):e2112674118.
Murray C, Galvan E, Ontiveros C, et al. Pharmacologic tumor PDL1 depletion with cefepime or ceftazidime promotes DNA damage and sensitivity to DNA-damaging agents. Int J Mol Sci. 2022;23(9):5129.
Bai H, Padron AS, Deng Y, et al. Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects. J Immunother Cancer. 2023;11(2):e004871.
Decout A, Katz JD, Venkatraman S, Ablasser A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol. 2021;21(9):548–569.
Zhai L, Spranger S, Binder DC, et al. Molecular pathways: targeting Ido1 and other tryptophan dioxygenases for cancer immunotherapy. Clin Cancer Res. 2015;21(24):5427–5433.
Zhai L, Ladomersky E, Lenzen A, et al. Ido1 in cancer: a Gemini of immune checkpoints. Cell Mol Immunol. 2018;15(5):447–457.
Liu M, Wang X, Wang L, et al. Targeting the Ido1 pathway in cancer: from bench to bedside. J Hematol Oncol. 2018;11(1):100.
Feng X, Tang R, Zhang R, et al. A comprehensive analysis of Ido1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers. J Cell Mol Med. 2020;24(9):5238–5248.
Grobben Y, de Man J, van Doornmalen AM, et al. Targeting indoleamine 2,3-dioxygenase in cancer models using the novel small molecule inhibitor NTRC 3883-0. Front Immunol. 2020;11:609490.
Odunsi K, Qian F, Lugade AA, et al. Metabolic adaptation of ovarian tumors in patients treated with an Ido1 inhibitor constrains antitumor immune responses. Sci Transl Med. 2022;14(636):eabg8402.
Shi D, Wu X, Jian Y, et al. USP14 promotes tryptophan metabolism and immune suppression by stabilizing Ido1 in colorectal cancer. Nat Commun. 2022;13(1):5644.
Choschzick M, Hantaredja W, Tennstedt P, Gieseking F, Wölber L, Simon R. Role of TP53 mutations in vulvar carcinomas. Int J Gynecol Pathol. 2011;30(5):497–504.
Amaral JD, Xavier JM, Steer CJ, Rodrigues CM. The role of p53 in apoptosis. Discov Med. 2010;9(45):145–152.
Nijman HW, Lambeck A, van der Burg SH, van der Zee AG, Daemen T. Immunologic aspect of ovarian cancer and p53 as tumor antigen. J Transl Med. 2005;3:34.
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma [published correction appears in Nature. 2012 Oct 11;490(7419):298]. Nature. 2011;474(7353):609–615.
Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511–1518.
Mielczarek-Palacz A, Sikora J, Kondera-Anasz Z, et al. The immune complex p53 protein/anti-p53 autoantibodies in the pathogenesis of ovarian serous carcinoma. Ginekol Pol. 2020;91(9):519, 253.
Goodell V, Salazar LG, Urban N, et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol. 2006;24(5):762–768.
Lambeck A, Leffers N, Hoogeboom BN, et al. P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy. Int J Cancer. 2007;121(3):606–614.
El-Arabey AA, Abdalla M, SnapShot Abd-Allah AR. TP53 status and macrophages infiltration in TCGA-analyzed tumors. Int Immunopharm. 2020;86:106758.
Hardwick NR, Frankel P, Ruel C, et al. p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy. Clin Cancer Res. 2018;24(6):1315–1325.
Leffers N, Lambeck AJA, Gooden MJM, et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase Ⅱ trial. Int J Cancer. 2009;125(9):2104–2113.
Vermeij R, Leffers N, Hoogeboom BN, et al. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase Ⅱ study. Int J Cancer. 2012;131(5):E670-E680.
Dijkgraaf EM, Santegoets SJ, Reyners AK, et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget. 2015;6(31):32228–32243.
Zhou M, Cheng H, Fu Y, Zhang J. Long noncoding RNA DARS-AS1 regulates TP53 ubiquitination and affects ovarian cancer progression by modulation miR-194-5p/RBX1 axis. J Biochem Mol Toxicol. 2021;35(10):e22865.
Min X, Zhang T, Lin Y, Wang B, Zhu K. Metformin inhibits the growth of ovarian cancer cells by promoting the Parkin-induced p53 ubiquitination. Biosci Rep. 2020:BSR20200679.
Zhang L, Jin Y, Yang H, et al. SMYD3 promotes epithelial ovarian cancer metastasis by downregulating p53 protein stability and promoting p53 ubiquitination. Carcinogenesis. 2019;40(12):1492–1503.
Wang S, Hao Q, Li J, et al. Ubiquitin ligase DTX3 empowers mutant p53 to promote ovarian cancer development. Genes Dis. 2022;9(3):705–716.
Chen Y, Hao Q, Wang J, et al. Ubiquitin ligase TRIM71 suppresses ovarian tumorigenesis by degrading mutant p53. Cell Death Dis. 2019;10(10):737.
Padmanabhan A, Candelaria N, Wong KK, et al. USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells. Nat Commun. 2018;9(1):1270.
Fucà G, Reppel L, Landoni E, Savoldo B, Dotti G. Enhancing chimeric antigen receptor T-cell efficacy in solid tumors. Clin Cancer Res. 2020;26(11):2444–2451.
Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147–167.
Chen J, Hu J, Gu L, et al. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Cancer Immunol Immunother. 2023;72(2):409–425.
Zhang Q, Liu G, Liu J, et al. The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice. Mol Ther Oncolytics. 2021;20:556–568.
Zhang Y, Wang P, Wang T, Fang Y, Ding Y, Qian Q. Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy. J Transl Med. 2021;19(1):82.
Liang Z, Dong J, Yang N, et al. Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer. Int J Biol Sci. 2021;17(15):4365–4376.
Shu R, Evtimov VJ, Hammett MV, et al. Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer. Mol Ther Oncolytics. 2021;20:325–341.
Sánchez-Paulete AR, Mateus-Tique J, Mollaoglu G, et al. Targeting macrophages with CAR T cells delays solid tumor progression and enhances antitumor immunity. Cancer Immunol Res. 2022;10(11):1354–1369.
Mabrouk N, Tran T, Sam I, et al. CXCR6 expressing T cells: functions and role in the control of tumors. Front Immunol. 2022;13:1022136.
Rodriguez-Garcia A, Lynn RC, Poussin M, et al. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat Commun. 2021;12(1):877.
Wang X, Cabrera FG, Sharp KL, Spencer DM, Foster AE, Bayle JH. Engineering tolerance toward allogeneic CAR-T cells by regulation of MHC surface expression with human Herpes virus-8 proteins. Mol Ther. 2021;29(2):718–733.
Kumar J, Kumar R, Kumar Singh A, et al. Deletion of Cbl-b inhibits CD8+ T-cell exhaustion and promotes CAR T-cell function. J Immunother Cancer. 2021;9(1):e001688.
Li W, Qiu S, Chen J, et al. Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy. Immunity. 2020;53(2):456–470.e6.
Zhao Q, Jiang Y, Xiang S, et al. Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons. Front Immunol. 2021;12:658753.
Liu Q, Li J, Zheng H, et al. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol Cancer. 2023;22(1):1–27.
Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv. 2023;9(7):eadf3700.
Wu JWY, Dand S, Doig L, et al. T-cell receptor therapy in the treatment of ovarian cancer: a mini review. Front Immunol. 2021;12:672502.
van Amerongen RA, Tuit S, Wouters AK, et al. PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer. Front Immunol. 2023;14:1121973.
Montesion M, Murugesan K, Jin DX, et al. Somatic HLA class Ⅰ loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov. 2021;11(2):282–292.
Kono M, Kumai T, Hayashi R, et al. Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery. Cancer Immunol Immunother. 2021;70(12):3421–3434.
Wang B, Niu D, Lai L, Ren EC. p53 increases MHC class Ⅰ expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1. Nat Commun. 2013;4:2359.
Pai SG, Carneiro BA, Mota JM, et al. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017;10(1):101.
Nguyen VHL, Hough R, Bernaudo S, Peng C. Wnt/β-catenin signalling in ovarian cancer: insights into its hyperactivation and function in tumorigenesis. J Ovarian Res. 2019;12(1):122.
Zhong Z, Sepramaniam S, Chew XH, et al. PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers. Oncogene. 2019;38(40):6662–6677.
Cho AR, Sul HJ, Kim YJ, Kim B, Zang DY. RNF43 R117fs mutant positively regulates Wnt/β-catenin signaling by failing to internalize FZD expressed on the cell surface. Sci Rep. 2022;12(1):7013.
Liu J, Xiao Q, Xiao J, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Targeted Ther. 2022;7(1):3.
Mao B, Wu W, Li Y, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature. 2001;411(6835):321–325.
Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218.
Betella I, Turbitt WJ, Szul T, et al. Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer. Gynecol Oncol. 2020;157(3):765–774.
Doo DW, Meza-Perez S, Londoño AI, et al. Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer. Ther Adv Med Oncol. 2020;12:1758835920913798.
Wall JA, Meza-Perez S, Scalise CB, et al. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy. Gynecol Oncol. 2021;160(1):285–294.
Dholakia J, Scalise CB, Katre AA, et al. Sequential modulation of the Wnt/β-catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance. Gynecol Oncol. 2022;164(1):170–180.
Ryland GL, Hunter SM, Doyle MA, et al. RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary. J Pathol. 2013;229(3):469–476.
Li Z, Wang Y, Li Y, et al. Ube2s stabilizes β-Catenin through K11-linked polyubiquitination to promote mesendoderm specification and colorectal cancer development. Cell Death Dis. 2018;9(5):456.
Hu W, Li M, Chen Y, Gu X. UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway. J Ovarian Res. 2021;14(1):121.
Liu D, Song Z, Wang X, Ouyang L. Ubiquitin C-terminal hydrolase L5 (UCHL5) accelerates the growth of endometrial cancer via activating the Wnt/β-catenin signaling pathway. Front Oncol. 2020;10:865.
Hu J, Meng Y, Yu T, Hu L, Mao M. Ubiquitin E3 ligase MARCH7 promotes ovarian tumor growth. Oncotarget. 2015;6(14):12174–12187.
Meng Y, Hu J, Chen Y, Yu T, Hu L. Silencing MARCH1 suppresses proliferation, migration and invasion of ovarian cancer SKOV3 cells via downregulation of NF-κB and Wnt/β-catenin pathways. Oncol Rep. 2016;36(5):2463–2470.
Li D, Zhang Z. TRIM37 promotes the aggressiveness of ovarian cancer cells and increases c-Myc expression by binding to HUWE1. Arch Biochem Biophys. 2022;728:109372.
Pan S, Chen R. Pathological implication of protein post-translational modifications in cancer. Mol Aspect Med. 2022;86:101097.
Cruz Walma DA, Chen Z, Bullock AN, Yamada KM. Ubiquitin ligases: guardians of mammalian development. Nat Rev Mol Cell Biol. 2022;23(5):350–367.
Aliabadi F, Sohrabi B, Mostafavi E, Pazoki-Toroudi H, Webster TJ. Ubiquitin-proteasome system and the role of its inhibitors in cancer therapy. Open Biol. 2021;11(4):200390.
Lange SM, Armstrong LA, Kulathu Y. Deubiquitinases: from mechanisms to their inhibition by small molecules. Mol Cell. 2022;82(1):15–29.
Pan W, Luo Q, Yan X, et al. A novel SMAC mimetic APG-1387 exhibits dual antitumor effect on HBV-positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti-tumor immunity. Biochem Pharmacol. 2018;154:127–135.
Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330.
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723.
Fu C, Zhu X, Xu P, Li Y. Pharmacological inhibition of USP7 promotes antitumor immunity and contributes to colon cancer therapy. OncoTargets Ther. 2019;12:609–617.
Fang DD, Tang Q, Kong Y, et al. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. J Immunother Cancer. 2019;7(1):327.
Nachmias B, Ashhab Y, Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol. 2004;14(4):231–243.
Huang Hk, Joazeiro CA, Bonfoco E, Kamada S, Leverson JD, Hunter T. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J Biol Chem. 2000;275(35):26661–26664.
Fulda S. Molecular pathways: targeting inhibitor of apoptosis proteins in cancer: from molecular mechanism to therapeutic application. Clin Cancer Res. 2014;20(2):289–295.
Infante JR, Dees EC, Olszanski AJ, et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2014;32(28):3103–3110.
DiPersio JF, Erba HP, Larson RA, et al. Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia — results of a phase Ⅰ dose-escalation study. Clin Lymphoma, Myeloma & Leukemia. 2015;15(7):443–449.
Noonan AM, Bunch KP, Chen JQ, et al. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer. 2016;122(4):588–597.
Xiao R, Allen CT, Tran L, et al. Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer. OncoImmunology. 2018;7(9):e1471440.
Kearney CJ, Lalaoui N, Freeman AJ, Ramsbottom KM, Silke J, Oliaro J. PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF. Cell Death Differ. 2017;24(10):1705–1716.
Chesi M, Mirza NN, Garbitt VM, et al. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med. 2016;22(12):1411–1420.
Beug ST, Beauregard CE, Healy C, et al. Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma [published correction appears in Nat Commun. 2018 Jul 18;9:16231]. Nat Commun. 2017;8:14278.
Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69(7):1237–1245.
Wang HQ, Mulford IJ, Sharp F, et al. Inhibition of MDM2 promotes antitumor responses in p53 wild-type cancer cells through their interaction with the immune and stromal microenvironment. Cancer Res. 2021;81(11):3079–3091.
Wang L, Kumar S, Dahiya S, et al. Ubiquitin-specific protease-7 inhibition impairs Tip60-dependent Foxp3 + T-regulatory cell function and promotes antitumor immunity. EBioMedicine. 2016;13:99–112.
Amaravadi Ravi K, Schilder Russell J, Martin Lainie P, et al. A phase Ⅰ study of the SMAC-mimetic birinapant in adults with refractory solid tumors or lymphoma. Mol Cancer Therapeut. 2015;14(11):2569–2575.
Igarashi Y, Sasada T. Cancer vaccines: toward the next breakthrough in cancer immunotherapy. J Immunol Res. 2020;2020:5825401.
Soumia M, Hajji H, El Mzibri M, et al. In-silico molecular modeling studies to identify novel potential inhibitors of HPV E6 protein. Vaccines. 2022;10(9):1452.
Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5(4):263–274.
Dougan M, Dougan S, Slisz J, et al. IAP inhibitors enhance co-stimulation to promote tumor immunity. J Exp Med. 2010;207(10):2195–2206.
Goodwin JG, Chunduru S, Kamat AM. Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL. J Leukoc Biol. 2012;92(1):233–244.
Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):119.
Michie J, Beavis PA, Freeman AJ, et al. Antagonism of IAPs enhances CAR T-cell efficacy. Cancer Immunol Res. 2019;7(2):183–192.
Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3(10):1148–1157.
Glassman PM, Balthasar JP. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol Med. 2014;11(1):20–33.
Kimiz-Gebologlu I, Gulce-Iz S, Biray-Avci C. Monoclonal antibodies in cancer immunotherapy. Mol Biol Rep. 2018;45(6):2935–2940.
Sathyanarayanan V, Neelapu SS. Cancer immunotherapy: strategies for personalization and combinatorial approaches. Mol Oncol. 2015;9(10):2043–2053.
Zhang M, Wen B, Anton OM, et al. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proc Natl Acad Sci U S A. 2018;115(46):E10915-E10924.
Hideshima T, Ogiya D, Liu J, et al. Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways. Leukemia. 2021;35(1):177–188.
Wei W, Lin Y, Song Z, et al. A20 and RBX1 regulate brentuximab vedotin sensitivity in Hodgkin lymphoma models. Clin Cancer Res. 2020;26(15):4093–4106.
Sun W, Wang X, Wang D, et al. CD40 × HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer. J Immunother Cancer. 2022;10(7):e005063.
Wertz IE, O'Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004;430(7000):694–699.
Li XY, Wu JC, Liu P, et al. Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma. Leukemia. 2023;37(1):164–177.
Wang G, Zhuang Z, Shen S, et al. Regulation of PTEN and ovarian cancer progression by an E3 ubiquitin ligase RBCK1. Hum Cell. 2022;35(3):896–908.
Yagi H, Onoyama I, Asanoma K, et al. Gα13-mediated LATS1 down-regulation contributes to epithelial-mesenchymal transition in ovarian cancer. Faseb J. 2019;33(12):13683–13694.
Liu W, Zhan Z, Zhang M, et al. KAT6A, a novel regulator of β-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1. Theranostics. 2021;11(13):6278–6292.
Saleh MN, Patel MR, Bauer TM, et al. Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53. Clin Cancer Res. 2021;27(19):5236–5247.
Zhou X, Sun SC. Targeting ubiquitin signaling for cancer immunotherapy. Signal Transduct Targeted Ther. 2021;6(1):16.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).